PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
The association between disease progression and PD-1/PD-L1 inhibitors in non-small cell lung cancer is unknown.
All articles by James Nam, PharmD
S-1 Plus Carboplatin May Be Effective in NSCLC Patients With Interstitial Lung Disease
Patients with severe complications, such as interstitial lung disease, are often excluded from clinical studies assessing chemotherapy in NSCLC.
Elotuzumab May Improve Outcomes Without Negatively Impacting HRQoL in Multiple Myeloma
Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.
High-Dose Busulfan Plus Melphalan Consolidation Therapy May Improve Outcomes in Ewing Sarcoma
Previous studies have suggested that high-dose therapy with busulfan plus melphalan may confer a benefit to patients with Ewing sarcoma compared with conventional chemotherapy.
Neoadjuvant Chemotherapy Before Radical Cystectomy May Improve Outcomes in Bladder Cancer
Researchers assess the outcomes of 5517 patients with bladder cancer who underwent radical cystectomy with or without neoadjuvant radiotherapy or chemotherapy.
Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma
Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.
Neoadjuvant ddMVAC May Lead to Improved Treatment Response in Bladder Cancer
Previous studies showed that ddMVAC is well tolerated, but how it compares with gemcitabine plus cisplatin in regard to cancer control and survival outcomes requires further investigation.
Stereotactic Body Radiation Therapy May Improve Localized Control in Oligometastatic RCC
Stereotactic body radiation therapy (SBRT) may be a safe and effective therapeutic option that couold provide localized control.
Gefitinib Continuation Therapy May Be Effective in NSCLC Post-Progression
Targeted therapies such as EGFR tyrosine kinase inhibitors have improved survival in non-small cell lung cancer, but resistance is a common challenge.
Systemic Therapy Post-Radiosurgery in RCC May Not Affect Outcomes
The impact of switching to or continuing treatment with systemic therapy post-stereotactic radiosurgery in renal cell carcinoma requires further study.
- Loading...
Loading...
Next post in Renal Cell Carcinoma
Loading... 
Loading...